Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases

Nitric oxide (NO) is a powerful mediator with biological activities such as vasodilation and prevention of vascular smooth muscle cell proliferation as well as functional regulation of cardiac cells. Thus, impaired production or reduced bioavailability of NO predisposes to the onset of different cardiovascular (CV) diseases. Alterations in the redox balance associated with excitation–contraction coupling have been identified in heart failure (HF), thus contributing to contractile abnormalities and arrhythmias. For its ability to influence cell proliferation and angiogenesis, NO may be considered a therapeutic option for the management of several CV diseases. Several clinical studies and trials investigated therapeutic NO strategies for systemic hypertension, atherosclerosis, and/or prevention of in stent restenosis, coronary heart disease (CHD), pulmonary arterial hypertension (PAH), and HF, although with mixed results in long-term treatment and effective dose administered in selected groups of patients. Tadalafil, sildenafil, and cinaguat were evaluated for the treatment of PAH, whereas vericiguat was investigated in the treatment of HF patients with reduced ejection fraction. Furthermore, supplementation with hydrogen sulfide, tetrahydrobiopterin, and nitrite/nitrate has shown beneficial effects at the vascular level.

[1]  X. Wehrens,et al.  Targeting pathological leak of ryanodine receptors: preclinical progress and the potential impact on treatments for cardiac arrhythmias and heart failure , 2019, Expert opinion on therapeutic targets.

[2]  E. Carluccio,et al.  Role of endothelial dysfunction in heart failure , 2019, Heart Failure Reviews.

[3]  G. Grassi,et al.  Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options , 2019, Heart Failure Reviews.

[4]  M. Sorrentino The Evolution from Hypertension to Heart Failure. , 2019, Heart failure clinics.

[5]  M. Alem Endothelial Dysfunction in Chronic Heart Failure: Assessment, Findings, Significance, and Potential Therapeutic Targets , 2019, International journal of molecular sciences.

[6]  T. Tipple,et al.  L-NAME releases nitric oxide and potentiates subsequent nitroglycerin-mediated vasodilation , 2019, Redox biology.

[7]  E. Egom Pulmonary Arterial Hypertension Due to NPR-C Mutation: A Novel Paradigm for Normal and Pathologic Remodeling? , 2019, International journal of molecular sciences.

[8]  J. Tanus-Santos,et al.  Mechanisms impairing blood pressure responses to nitrite and nitrate. , 2019, Nitric oxide : biology and chemistry.

[9]  Zhi-gang Guo,et al.  Chronic stress: a critical risk factor for atherosclerosis , 2019, The Journal of international medical research.

[10]  C. Napoli,et al.  Effect of nitric oxide reduction on arterial thrombosis , 2019, Scandinavian cardiovascular journal : SCJ.

[11]  A. Soricelli,et al.  Epigenetic Hallmarks of Fetal Early Atherosclerotic Lesions in Humans , 2018, JAMA cardiology.

[12]  A. Voors,et al.  Treating oxidative stress in heart failure: past, present and future , 2018, European journal of heart failure.

[13]  A. Karimpour-Fard,et al.  Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro , 2018, Circulation. Heart failure.

[14]  U. Walter,et al.  Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. , 2018, Nitric oxide : biology and chemistry.

[15]  S. Ravindran,et al.  Effect of Sodium Thiosulfate Postconditioning on Ischemia-Reperfusion Injury Induced Mitochondrial Dysfunction in Rat Heart , 2018, Journal of Cardiovascular Translational Research.

[16]  R. Feil,et al.  cGMP Signaling and Vascular Smooth Muscle Cell Plasticity , 2018, Journal of cardiovascular development and disease.

[17]  M. Ghasemi,et al.  Nitric Oxide and Mitochondrial Function in Neurological Diseases , 2018, Neuroscience.

[18]  S. Archer,et al.  Pulmonary arterial hypertension: pathogenesis and clinical management , 2018, British Medical Journal.

[19]  J. Balligand,et al.  Nitric oxide signalling in cardiovascular health and disease , 2018, Nature Reviews Cardiology.

[20]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[21]  Pierre Leroy,et al.  Regulation of protein function by S-nitrosation and S-glutathionylation: processes and targets in cardiovascular pathophysiology , 2017, Biological chemistry.

[22]  Daniel W. Jones,et al.  Potential U.S. Population Impact of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline , 2017 .

[23]  A. Panov,et al.  Physiological Levels of Nitric Oxide Diminish Mitochondrial Superoxide. Potential Role of Mitochondrial Dinitrosyl Iron Complexes and Nitrosothiols , 2017, Front. Physiol..

[24]  Hiroshi Watanabe Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator. , 2017, European cardiology.

[25]  P. Ponikowski,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. , 2017, JACC. Heart failure.

[26]  X. Teng,et al.  Hydrogen sulfide ameliorated L-NAME-induced hypertensive heart disease by the Akt/eNOS/NO pathway , 2017, Experimental biology and medicine.

[27]  S. Rosenkranz,et al.  RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors , 2017, European Respiratory Journal.

[28]  M. Anand-Srivastava,et al.  Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling , 2017, PloS one.

[29]  F. Chen,et al.  Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension , 2017, Antioxidants.

[30]  M. Beghetti,et al.  Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension , 2017, BMC Cardiovascular Disorders.

[31]  P. Olofsson,et al.  Dietary nitrate attenuates renal ischemia-reperfusion injuries by modulation of immune responses and reduction of oxidative stress , 2017, Redox biology.

[32]  P. Ponikowski,et al.  Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study , 2017, European journal of heart failure.

[33]  T. Murohara,et al.  Diallyl Trisulfide Augments Ischemia-Induced Angiogenesis via an Endothelial Nitric Oxide Synthase-Dependent Mechanism. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[34]  L. Santhanam,et al.  Impaired Hydrogen Sulfide–Mediated Vasodilation Contributes to Microvascular Endothelial Dysfunction in Hypertensive Adults , 2017, Hypertension.

[35]  Mingyu Liang,et al.  Malate and Aspartate Increase L-Arginine and Nitric Oxide and Attenuate Hypertension. , 2017, Cell reports.

[36]  Sanjiv J. Shah,et al.  Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.

[37]  Kedar Ghimire,et al.  Nitric oxide: what's new to NO? , 2017, American journal of physiology. Cell physiology.

[38]  Min Zhang,et al.  Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension , 2017, BMC Pulmonary Medicine.

[39]  U. Förstermann,et al.  Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis , 2017, Circulation research.

[40]  A. Voors,et al.  Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension , 2017, European journal of heart failure.

[41]  J. Balligand,et al.  New and Emerging Therapies and Targets: Beta-3 Agonists. , 2016, Handbook of experimental pharmacology.

[42]  M. Hezel,et al.  Dietary nitrate improves age-related hypertension and metabolic abnormalities in rats via modulation of angiotensin II receptor signaling and inhibition of superoxide generation. , 2016, Free radical biology & medicine.

[43]  Vagheesh M. Narasimhan,et al.  Extensive Proliferation of a Subset of Differentiated, yet Plastic, Medial Vascular Smooth Muscle Cells Contributes to Neointimal Formation in Mouse Injury and Atherosclerosis Models , 2016, Circulation research.

[44]  M. Rychter,et al.  S-Nitrosothiols-NO donors regulating cardiovascular cell proliferation: Insight into intracellular pathway alterations. , 2016, The international journal of biochemistry & cell biology.

[45]  M. Seager,et al.  Guanylate cyclase stimulators for pulmonary hypertension. , 2016, The Cochrane database of systematic reviews.

[46]  D. Lefer,et al.  pH-Controlled Hydrogen Sulfide Release for Myocardial Ischemia-Reperfusion Injury. , 2016, Journal of the American Chemical Society.

[47]  L. Morbidelli,et al.  Anti-hypertensive property of a nickel-piperazine/NO donor in spontaneously hypertensive rats. , 2016, Pharmacological research.

[48]  M. Humbert,et al.  Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. , 2016, The Lancet. Respiratory medicine.

[49]  W. Paulus,et al.  Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. , 2016, JACC. Heart failure.

[50]  Sanjiv J. Shah,et al.  Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.

[51]  J. Thompson,et al.  S-Nitrosylation of Sarcomeric Proteins Depresses Myofilament Ca2+)Sensitivity in Intact Cardiomyocytes. , 2015, Antioxidants & redox signaling.

[52]  R. D. de Boer,et al.  Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. , 2015, European heart journal.

[53]  Y. Weng,et al.  Nitric oxide producing coating mimicking endothelium function for multifunctional vascular stents. , 2015, Biomaterials.

[54]  V. Lemos,et al.  The new nitric oxide donor cyclohexane nitrate induces vasorelaxation, hypotension, and antihypertensive effects via NO/cGMP/PKG pathway , 2015, Front. Physiol..

[55]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[56]  J. Zweier,et al.  Depletion of NADP(H) due to CD38 activation triggers endothelial dysfunction in the postischemic heart , 2015, Proceedings of the National Academy of Sciences.

[57]  A. Lenzi,et al.  Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications , 2015, Journal of Endocrinological Investigation.

[58]  S. Snyder,et al.  Protein kinase G–regulated production of H2S governs oxygen sensing , 2015, Science Signaling.

[59]  Peter Van Buren,et al.  Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin , 2015, Circulation.

[60]  M. Verhaar,et al.  Beneficial effects of diminished production of hydrogen sulfide or carbon monoxide on hypertension and renal injury induced by NO withdrawal , 2015, British journal of pharmacology.

[61]  J. Marín-García,et al.  Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart , 2015, Heart Failure Reviews.

[62]  M. Caulfield,et al.  Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. , 2015, Hypertension.

[63]  S. Antoniou,et al.  Randomized Phase 2 Trial of Intracoronary Nitrite During Acute Myocardial Infarction , 2015, Circulation research.

[64]  C. Stefanadis,et al.  Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches. , 2014, Pharmacology & therapeutics.

[65]  Adriana V Treuer,et al.  Nitric oxide synthases, S-nitrosylation and cardiovascular health: From molecular mechanisms to therapeutic opportunities (Review) , 2014, Molecular medicine reports.

[66]  W. Linke,et al.  Emerging importance of oxidative stress in regulating striated muscle elasticity , 2014, Journal of Muscle Research and Cell Motility.

[67]  S. Frisbee,et al.  Protective effect of sex on chronic stress- and depressive behavior-induced vascular dysfunction in BALB/cJ mice. , 2014, Journal of applied physiology.

[68]  J. Hare,et al.  Interaction Between Neuronal Nitric Oxide Synthase Signaling and Temperature Influences Sarcoplasmic Reticulum Calcium Leak: Role of Nitroso–Redox Balance , 2014, Circulation research.

[69]  P. Collinson,et al.  Effects of nebivolol on biomarkers in elderly patients with heart failure. , 2014, International journal of cardiology.

[70]  S. Shyue,et al.  Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis , 2014, Acta physiologica.

[71]  W. Toff,et al.  Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI) , 2014, European heart journal.

[72]  T. Murohara,et al.  Hydrogen Sulfide Attenuates Cardiac Dysfunction After Heart Failure Via Induction of Angiogenesis , 2013, Circulation. Heart failure.

[73]  S. Nattel,et al.  Regulation of cardiac nitric oxide signaling by nuclear β-adrenergic and endothelin receptors. , 2013, Journal of molecular and cellular cardiology.

[74]  S. Rosenkranz,et al.  Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): A randomized, double-blind, placebo-controlled, single-dose study , 2013 .

[75]  B. Merkely,et al.  Cinaciguat prevents neointima formation after arterial injury by decreasing vascular smooth muscle cell migration and proliferation. , 2013, International journal of cardiology.

[76]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[77]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[78]  C. Napoli,et al.  Effects of nitric oxide on cell proliferation: novel insights. , 2013, Journal of the American College of Cardiology.

[79]  J. Jang,et al.  Myofilament Ca2+ desensitization mediates positive lusitropic effect of neuronal nitric oxide synthase in left ventricular myocytes from murine hypertensive heart. , 2013, Journal of molecular and cellular cardiology.

[80]  Linda Partridge,et al.  Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I , 2013, Nature Medicine.

[81]  K. Cho,et al.  Impact of Chronic Emotional Stress on Myocardial Function in Postmenopausal Women and Its Relationship with Endothelial Dysfunction , 2013, Korean circulation journal.

[82]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[83]  D. Kass,et al.  Nitric oxide synthases in heart failure. , 2013, Antioxidants & redox signaling.

[84]  L. Skovgaard,et al.  Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction in Patients With Preserved Ejection Fraction: The Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) Trial , 2013, Circulation.

[85]  J. Loscalzo,et al.  S-nitrosothiols and the S-nitrosoproteome of the cardiovascular system. , 2013, Antioxidants & redox signaling.

[86]  S. Umemura,et al.  Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. , 2012, Journal of the American College of Cardiology.

[87]  M. Crabtree,et al.  Regulation of Endothelial Nitric-oxide Synthase (NOS) S-Glutathionylation by Neuronal NOS , 2012, The Journal of Biological Chemistry.

[88]  J. Stamler,et al.  Aberrant S-nitrosylation mediates calcium-triggered ventricular arrhythmia in the intact heart , 2012, Proceedings of the National Academy of Sciences.

[89]  D. Wink,et al.  Nitroxyl-Mediated Disulfide Bond Formation Between Cardiac Myofilament Cysteines Enhances Contractile Function , 2012, Circulation research.

[90]  B. Brundage,et al.  Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. , 2012, Journal of the American College of Cardiology.

[91]  M. Suematsu,et al.  Hydrogen sulfide anion regulates redox signaling via electrophile sulfhydration. , 2012, Nature chemical biology.

[92]  S. Bhushan,et al.  The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. , 2012, American journal of physiology. Heart and circulatory physiology.

[93]  M. Wolin Novel role for the regulation of mitochondrial fission by hypoxia inducible factor-1α in the control of smooth muscle remodeling and progression of pulmonary hypertension. , 2012, Circulation research.

[94]  D. Kass,et al.  Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. , 2012, Journal of the American College of Cardiology.

[95]  U. Förstermann,et al.  Nitric oxide synthases: regulation and function. , 2012, European heart journal.

[96]  J. Francis,et al.  Systemic and Vascular Oxidation Limits the Efficacy of Oral Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease , 2012, Circulation.

[97]  J. Stasch,et al.  Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. , 2012, American journal of physiology. Heart and circulatory physiology.

[98]  W. Linke,et al.  Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo , 2011, Circulation.

[99]  J. Stamler,et al.  Regulation by S-Nitrosylation of Protein Post-translational Modification* , 2011, The Journal of Biological Chemistry.

[100]  M. Endres,et al.  Stress Worsens Endothelial Function and Ischemic Stroke via Glucocorticoids , 2011, Stroke.

[101]  T. Fleming,et al.  Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.

[102]  R. Oudiz,et al.  Conversion From Sildenafil To Tadalafil: Initial Results From The Sildenafil To Tadalafil In Pulmonary Arterial Hypertension (SITAR) Study , 2011, ATS 2011.

[103]  G. Figtree,et al.  &bgr;3 Adrenergic Stimulation of the Cardiac Na+-K+ Pump by Reversal of an Inhibitory Oxidative Modification , 2010, Circulation.

[104]  J. Tamargo,et al.  Cardiac electrophysiological effects of nitric oxide. , 2010, Cardiovascular research.

[105]  J. Stasch,et al.  Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models , 2010, Journal of hypertension.

[106]  J. Hare,et al.  Impaired S-Nitrosylation of the Ryanodine Receptor Caused by Xanthine Oxidase Activity Contributes to Calcium Leak in Heart Failure* , 2010, The Journal of Biological Chemistry.

[107]  Xinli Hu,et al.  Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart , 2010, Circulation.

[108]  A. Abbate,et al.  Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide , 2009, Circulation.

[109]  F. Atienza,et al.  Nitric Oxide Increases Cardiac IK1 by Nitrosylation of Cysteine 76 of Kir2.1 Channels , 2009, Circulation research.

[110]  Mark J. Kohr,et al.  Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. , 2009, Journal of molecular and cellular cardiology.

[111]  M. Ashraf,et al.  Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury. , 2009, American journal of physiology. Heart and circulatory physiology.

[112]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[113]  Lei Xi,et al.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[114]  T. Furukawa,et al.  Redox- and Calmodulin-dependent S-Nitrosylation of the KCNQ1 Channel* , 2009, Journal of Biological Chemistry.

[115]  R. Schwinger,et al.  Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium. , 2009, Journal of cardiac failure.

[116]  Mark J. Kohr,et al.  Nitric oxide signaling and the regulation of myocardial function. , 2008, Journal of molecular and cellular cardiology.

[117]  C. Napoli,et al.  Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits. , 2008, Nitric oxide : biology and chemistry.

[118]  A. Shah,et al.  Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling , 2008, Circulation.

[119]  A. Quyyumi,et al.  Tetrahydrobiopterin: a novel antihypertensive therapy , 2008, Journal of Human Hypertension.

[120]  Mark J. Kohr,et al.  Endothelial nitric oxide synthase decreases beta-adrenergic responsiveness via inhibition of the L-type Ca2+ current. , 2008, American journal of physiology. Heart and circulatory physiology.

[121]  C. Napoli,et al.  Effects of a pomegranate fruit extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis. , 2007, Cardiovascular research.

[122]  Claudio Napoli,et al.  Rethinking primary prevention of atherosclerosis-related diseases. , 2006, Circulation.

[123]  C. Napoli,et al.  Nitric oxide and atherosclerosis: an update. , 2006, Nitric oxide : biology and chemistry.

[124]  B. Casadei,et al.  Are myocardial eNOS and nNOS involved in the beta-adrenergic and muscarinic regulation of inotropy? A systematic investigation. , 2006, Cardiovascular research.

[125]  R. Saraiva,et al.  Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy , 2006, Circulation research.

[126]  S. Neubauer,et al.  nNOS Gene Deletion Exacerbates Pathological Left Ventricular Remodeling and Functional Deterioration After Myocardial Infarction , 2005, Circulation.

[127]  R. Saraiva,et al.  Deficiency of Neuronal Nitric Oxide Synthase Increases Mortality and Cardiac Remodeling After Myocardial Infarction: Role of Nitroso-Redox Equilibrium , 2005, Circulation.

[128]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[129]  D. Kass,et al.  Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. , 2005, The Journal of clinical investigation.

[130]  C. Napoli,et al.  Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[131]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[132]  Stuart D Katz,et al.  Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.

[133]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[134]  J. Balligand,et al.  Cardiomyocyte-Restricted Overexpression of Endothelial Nitric Oxide Synthase (NOS3) Attenuates &bgr;-Adrenergic Stimulation and Reinforces Vagal Inhibition of Cardiac Contraction , 2004, Circulation.

[135]  J. Hare Spatial confinement of isoforms of cardiac nitric-oxide synthase: unravelling the complexities of nitric oxide's cardiobiology , 2004, The Lancet.

[136]  G. D. Johnston,et al.  Functional Consequences of Endothelial Nitric Oxide Synthase Uncoupling in Congestive Cardiac Failure , 2003, Circulation.

[137]  E. Ashley,et al.  Cardiac Nitric Oxide Synthase 1 Regulates Basal and &bgr;-Adrenergic Contractility in Murine Ventricular Myocytes , 2002, Circulation.

[138]  C. Napoli,et al.  Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. , 2002, Cardiovascular research.

[139]  Douglas L. Jones,et al.  Mortality After Myocardial Infarction in Mice , 2022 .

[140]  P. Vollenweider,et al.  Insulin Resistance, Hyperlipidemia, and Hypertension in Mice Lacking Endothelial Nitric Oxide Synthase , 2001, Circulation.

[141]  C. Napoli,et al.  Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. , 2001, Mayo Clinic proceedings.

[142]  C. Napoli,et al.  Nitric oxide and atherosclerosis. , 2001, Nitric oxide : biology and chemistry.

[143]  T. Meinertz,et al.  Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus , 2000, Diabetologia.

[144]  J. Bronzwaer,et al.  Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. , 1999, Circulation.

[145]  N. Takahashi,et al.  Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. , 1998, The Journal of clinical investigation.

[146]  M. Hori,et al.  Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. , 1997, Hypertension.

[147]  A. Quyyumi,et al.  Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.

[148]  S. Moncada,et al.  Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. , 1992, Journal of hypertension.

[149]  A. Quyyumi,et al.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.

[150]  M. Anand-Srivastava,et al.  Sodium nitroprusside attenuates hyperproliferation of vascular smooth muscle cells from spontaneously hypertensive rats through the inhibition of overexpression of AT1 receptor, cell cycle proteins and c-Src/growth factor receptor signaling pathways. , 2019, Canadian journal of physiology and pharmacology.

[151]  R. Correa-Rotter,et al.  New 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline: Healthcare Impact in Mexico and Other Developing Countries , 2019, Hypertension.

[152]  R. Benza,et al.  sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension. , 2017, Respiratory medicine.

[153]  M. Totzeck,et al.  Nitrite-Nitric Oxide Signaling and Cardioprotection. , 2017, Advances in experimental medicine and biology.

[154]  C. Szabó Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications. , 2017, American journal of physiology. Cell physiology.

[155]  D. Jourd’heuil,et al.  A Brief Overview of Nitric Oxide and Reactive Oxygen Species Signaling in Hypoxia-Induced Pulmonary Hypertension. , 2017, Advances in experimental medicine and biology.

[156]  L. Ghiadoni,et al.  The Endothelium as a Target for Chronic Stress. , 2017, American journal of hypertension.

[157]  R. Teng,et al.  Biomarkers in Lung Diseases : from Pathogenesis to Prediction to New Therapies Decreased endothelial nitric oxide synthase expression and function contribute to impaired mitochondrial biogenesis and oxidative stress in fetal lambs with persistent pulmonary hypertension , 2015 .

[158]  A. Mebazaa,et al.  Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. , 2013, European heart journal.

[159]  T. Adachi Modulation of vascular sarco/endoplasmic reticulum calcium ATPase in cardiovascular pathophysiology. , 2010, Advances in pharmacology.

[160]  Yong Liu,et al.  Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. , 2009, Cardiovascular research.

[161]  R. Brandes,et al.  - Role of endothelium-derived nitric oxide , 2007 .

[162]  F. Zannad,et al.  Effect of MR Blockade on Collagen Formation and Cardiovascular Disease with a Specific Emphasis on Heart Failure , 2005, Heart Failure Reviews.

[163]  J. Bronzwaer,et al.  Myocardial Contractile Effects of Nitric Oxide , 2004, Heart Failure Reviews.